Click here to get full coverage on How The Day One Deal Is Reshaping The Story For Mersana Therapeutics (MRSN) - Yahoo Finance

How The Day One Deal Is Reshaping The Story For Mersana Therapeutics (MRSN)  Yahoo Finance

How The Day One Deal Is Reshaping The Story For Mersana Therapeutics (MRSN) - Yahoo Finance

Click here to get full coverage on Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights - PR Newswire

Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights  PR Newswire

Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights - PR Newswire

Click here to get full coverage on $MRSN stock is up 214% today. Here's what we see in our data. - Quiver Quantitative

$MRSN stock is up 214% today. Here's what we see in our data.  Quiver Quantitative

$MRSN stock is up 214% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - Stocktwits

MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal  Stocktwits

MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - Stocktwits

Click here to get full coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 26% Yet Its Low P/S Is No Reason For Excitement - simplywall.st

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 26% Yet Its Low P/S Is No Reason For Excitement  simplywall.st

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 26% Yet Its Low P/S Is No Reason For Excitement - simplywall.st

Click here to get full coverage on Mersana Therapeutics (NASDAQ: MRSN) to host Nov. 14 results call at 8:00 a.m. ET - Stock Titan

Mersana Therapeutics (NASDAQ: MRSN) to host Nov. 14 results call at 8:00 a.m. ET  Stock Titan

Mersana Therapeutics (NASDAQ: MRSN) to host Nov. 14 results call at 8:00 a.m. ET - Stock Titan

Click here to get full coverage on Biotech Stock Catapults 200% On Surprise Takeover - Investor's Business Daily

Biotech Stock Catapults 200% On Surprise Takeover  Investor's Business Daily

Biotech Stock Catapults 200% On Surprise Takeover - Investor's Business Daily

Click here to get full coverage on Why Is Mersana Therapeutics Stock (MRSN) Up Today? - TipRanks

Why Is Mersana Therapeutics Stock (MRSN) Up Today?  TipRanks

Why Is Mersana Therapeutics Stock (MRSN) Up Today? - TipRanks

Click here to get full coverage on Why Is Mersana (MRSN) Up 200% in Premarket? Day One Biopharma Agrees to $25/Share Buyout - Tokenist

Why Is Mersana (MRSN) Up 200% in Premarket? Day One Biopharma Agrees to $25/Share Buyout  Tokenist

Why Is Mersana (MRSN) Up 200% in Premarket? Day One Biopharma Agrees to $25/Share Buyout - Tokenist

Click here to get full coverage on Mersana Therapeutics, Inc. (MRSN) Day One Biopharmaceuticals, Inc., - M&A Call - Slideshow - Seeking Alpha

Mersana Therapeutics, Inc. (MRSN) Day One Biopharmaceuticals, Inc., - M&A Call - Slideshow  Seeking Alpha

Mersana Therapeutics, Inc. (MRSN) Day One Biopharmaceuticals, Inc., - M&A Call - Slideshow - Seeking Alpha

Click here to get full coverage on Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights - PR Newswire

Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights  PR Newswire

Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights - PR Newswire

Click here to get full coverage on Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates  Yahoo Finance

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $MRSN Given $30.75 Price Target - Quiver Quantitative

New Analyst Forecast: $MRSN Given $30.75 Price Target  Quiver Quantitative

New Analyst Forecast: $MRSN Given $30.75 Price Target - Quiver Quantitative

Click here to get full coverage on Rainbows and Unicorns: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Just Became A Lot More Optimistic - simplywall.st

Rainbows and Unicorns: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Just Became A Lot More Optimistic  simplywall.st

Rainbows and Unicorns: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Analysts Just Became A Lot More Optimistic - simplywall.st

Click here to get full coverage on Mersana (NASDAQ: MRSN) to be acquired by Day One: $25/sh cash, CVRs up to $30.25 - Stock Titan

Mersana (NASDAQ: MRSN) to be acquired by Day One: $25/sh cash, CVRs up to $30.25  Stock Titan

Mersana (NASDAQ: MRSN) to be acquired by Day One: $25/sh cash, CVRs up to $30.25 - Stock Titan

Click here to get full coverage on Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights - PR Newswire

Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights  PR Newswire

Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights - PR Newswire

Click here to get full coverage on Pre-commencement TO-C: Day One to buy all Mersana shares - Stock Titan

Pre-commencement TO-C: Day One to buy all Mersana shares  Stock Titan

Pre-commencement TO-C: Day One to buy all Mersana shares - Stock Titan

Click here to get full coverage on Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights - PR Newswire

Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights  PR Newswire

Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights - PR Newswire

Click here to get full coverage on HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN - PR Newswire

HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN  PR Newswire

HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the Merger - EXAS, SEE, CDTX, and MRSN - PR Newswire

Click here to get full coverage on Day One to buy Mersana Therapeutics for $25/share upfront (DAWN:NASDAQ) - Seeking Alpha

Day One to buy Mersana Therapeutics for $25/share upfront (DAWN:NASDAQ)  Seeking Alpha

Day One to buy Mersana Therapeutics for $25/share upfront (DAWN:NASDAQ) - Seeking Alpha

Click here to get full coverage on Mersana Therapeutics (MRSN) Downgraded by BTIG to Neutral | MRSN Stock News - GuruFocus

Mersana Therapeutics (MRSN) Downgraded by BTIG to Neutral | MRSN Stock News  GuruFocus

Mersana Therapeutics (MRSN) Downgraded by BTIG to Neutral | MRSN Stock News - GuruFocus

Click here to get full coverage on MRSN Stock Soars 201% After Acquisition by Day One Biopharma - GuruFocus

MRSN Stock Soars 201% After Acquisition by Day One Biopharma  GuruFocus

MRSN Stock Soars 201% After Acquisition by Day One Biopharma - GuruFocus

Click here to get full coverage on MRSN Misses Q3 Revenue Estimates Amid Solid Cash Position - GuruFocus

MRSN Misses Q3 Revenue Estimates Amid Solid Cash Position  GuruFocus

MRSN Misses Q3 Revenue Estimates Amid Solid Cash Position - GuruFocus

Click here to get full coverage on Mersana Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - Quiver Quantitative

Mersana Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025  Quiver Quantitative

Mersana Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - Quiver Quantitative

Click here to get full coverage on MRSN: Guggenheim Downgrades Mersana Therapeutics to Neutral | MR - GuruFocus

MRSN: Guggenheim Downgrades Mersana Therapeutics to Neutral | MR  GuruFocus

MRSN: Guggenheim Downgrades Mersana Therapeutics to Neutral | MR - GuruFocus

Click here to get full coverage on WRAIR- MULTIDRUG-RESISTANT ORGANISM REPOSITORY AND SURVEILLANCE NETWORK (MRSN) - DVIDS

WRAIR- MULTIDRUG-RESISTANT ORGANISM REPOSITORY AND SURVEILLANCE NETWORK (MRSN)  DVIDS

WRAIR- MULTIDRUG-RESISTANT ORGANISM REPOSITORY AND SURVEILLANCE NETWORK (MRSN) - DVIDS

Click here to get full coverage on Day One Biopharmaceuticals (DAWN) to Acquire Mersana Therapeutics (MRSN) in $285M Deal - GuruFocus

Day One Biopharmaceuticals (DAWN) to Acquire Mersana Therapeutics (MRSN) in $285M Deal  GuruFocus

Day One Biopharmaceuticals (DAWN) to Acquire Mersana Therapeutics (MRSN) in $285M Deal - GuruFocus

Click here to get full coverage on User - The Chronicle-Journal

User - The Chronicle-Journal

Click here to get full coverage on MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - Asianet Newsable

MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal  Asianet Newsable

MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - Asianet Newsable

Click here to get full coverage on Mersana Therapeutics (MRSN) Stock Forecast and Price Target 2026 - MarketBeat

Mersana Therapeutics (MRSN) Stock Forecast and Price Target 2026  MarketBeat

Mersana Therapeutics (MRSN) Stock Forecast and Price Target 2026 - MarketBeat

Click here to get full coverage on MRSN Forecast — Price Prediction for 2026. Should I Buy MRSN? - Intellectia AI

MRSN Forecast — Price Prediction for 2026. Should I Buy MRSN?  Intellectia AI

MRSN Forecast — Price Prediction for 2026. Should I Buy MRSN? - Intellectia AI

Click here to get full coverage on What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings - GuruFocus

What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings  GuruFocus

What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings - GuruFocus

Click here to get full coverage on Mersana Therapeutics Stock Price Forecast. Should You Buy MRSN? - StockInvest.us

Mersana Therapeutics Stock Price Forecast. Should You Buy MRSN?  StockInvest.us

Mersana Therapeutics Stock Price Forecast. Should You Buy MRSN? - StockInvest.us

Click here to get full coverage on Mersana Therapeutics Stock: Still In 'Show Me' Territory (NASDAQ:MRSN) - Seeking Alpha

Mersana Therapeutics Stock: Still In 'Show Me' Territory (NASDAQ:MRSN)  Seeking Alpha

Mersana Therapeutics Stock: Still In 'Show Me' Territory (NASDAQ:MRSN) - Seeking Alpha

Click here to get full coverage on Mersana Therapeutics (NASDAQ: MRSN) down 73% on ovarian cancer trial fail - Dhaka Tribune

Mersana Therapeutics (NASDAQ: MRSN) down 73% on ovarian cancer trial fail  Dhaka Tribune

Mersana Therapeutics (NASDAQ: MRSN) down 73% on ovarian cancer trial fail - Dhaka Tribune

Click here to get full coverage on Mersana Therapeutics (MRSN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat

Mersana Therapeutics (MRSN) Short Interest & Short Float | Updated Apr 2026  MarketBeat

Mersana Therapeutics (MRSN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat

Click here to get full coverage on MRSN Stock Price, Quote & Chart | MERSANA THERAPEUTICS INC (NASDAQ:MRSN) - ChartMill

MRSN Stock Price, Quote & Chart | MERSANA THERAPEUTICS INC (NASDAQ:MRSN)  ChartMill

MRSN Stock Price, Quote & Chart | MERSANA THERAPEUTICS INC (NASDAQ:MRSN) - ChartMill

Click here to get full coverage on Mersana Therapeutics (MRSN) Stock Price, News & Analysis - MarketBeat

Mersana Therapeutics (MRSN) Stock Price, News & Analysis  MarketBeat

MRSN

Price Chart

Key Statistics

Technicals

About MRSN

Latest News

How The Day One Deal Is Reshaping The Story For Mersana Therapeutics (MRSN) - Yahoo Finance

Halper Sadeh LLC Encourages CDTX, MRSN, HOLX Shareholders to Contact the Firm to Discuss Their Rights - PR Newswire

$MRSN stock is up 214% today. Here's what we see in our data. - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers